DK2765990T3 - Faststofdispersion - Google Patents

Faststofdispersion

Info

Publication number: DK2765990T3
Authority: DK; Denmark
Prior art keywords: solids; dispersion
Prior art date: 2011-10-14

Application number

DK12809373.9T

Other languages

English (en)

Inventor

David Shank Fry

Christopher M Lindemann

Michael Preigh

Corey Jay Bloom

Christopher Donovan Craig

Devon Brevard Dubose

Jeff Gautschi

Dan Smithey

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-14

Filing date

2012-10-12

Publication date

2017-11-13

2012-10-12 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2017-11-13 Application granted granted Critical

2017-11-13 Publication of DK2765990T3 publication Critical patent/DK2765990T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Dispersion Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Glass Compositions (AREA)
Inorganic Insulating Materials (AREA)
Optical Communication System (AREA)

DK12809373.9T 2011-10-14 2012-10-12 Faststofdispersion DK2765990T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161547620P	2011-10-14	2011-10-14
US201261606207P	2012-03-02	2012-03-02
PCT/US2012/060044 WO2013056108A2 (en)	2011-10-14	2012-10-12	Solid dispersion

Publications (1)

Publication Number	Publication Date
DK2765990T3 true DK2765990T3 (da)	2017-11-13

Family

ID=47471981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK12809373.9T DK2765990T3 (da)	2011-10-14	2012-10-12	Faststofdispersion

Country Status (33)

Country	Link
US (5)	US9457093B2 (da)
EP (1)	EP2765990B1 (da)
JP (2)	JP5944514B2 (da)
KR (1)	KR102000312B1 (da)
CN (3)	CN108498465B (da)
AU (3)	AU2012322039C1 (da)
BR (2)	BR112014009092B1 (da)
CA (2)	CA3114454C (da)
CL (1)	CL2014000930A1 (da)
CO (1)	CO6960547A2 (da)
CR (1)	CR20140228A (da)
CY (1)	CY1119837T1 (da)
DK (1)	DK2765990T3 (da)
ES (1)	ES2650608T3 (da)
HR (1)	HRP20171578T1 (da)
HU (1)	HUE035247T2 (da)
IL (1)	IL232103B (da)
LT (1)	LT2765990T (da)
ME (1)	ME02913B (da)
MX (1)	MX353970B (da)
MY (1)	MY169072A (da)
NO (1)	NO2021029I1 (da)
PH (1)	PH12014500799B1 (da)
PL (1)	PL2765990T3 (da)
PT (1)	PT2765990T (da)
RS (1)	RS56608B1 (da)
RU (1)	RU2648448C2 (da)
SG (1)	SG11201401459YA (da)
SI (1)	SI2765990T1 (da)
SM (1)	SMT201700499T1 (da)
TW (3)	TWI594769B (da)
WO (1)	WO2013056108A2 (da)
ZA (1)	ZA201606123B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2765990T3 (da) *	2011-10-14	2017-11-13	Array Biopharma Inc	Faststofdispersion
KR20200003245A (ko)	2011-10-14	2020-01-08	어레이 바이오파마 인크.	선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
TR201808450T4 (tr) *	2012-03-23	2018-07-23	Array Biopharma Inc	Beyin kanserinin tedavisinde kullanılmaya yönelik amorf katı dispersiyon.
US9670158B2 (en) *	2013-07-19	2017-06-06	Siga Technologies, Inc.	Amorphous tecovirimat preparation
EP3082803A4 (en) *	2013-12-20	2017-05-31	Phosphorex Inc.	Indirubin solid dispersion composition
KR102448369B1 (ko)	2014-02-05	2022-09-28	머크 샤프 앤드 돔 엘엘씨	Cgrp-활성 화합물에 대한 정제 제제
EP3307246A1 (en)	2015-06-09	2018-04-18	Capsugel Belgium NV	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107126419B (zh) *	2016-02-26	2020-06-19	石药集团中诺药业（石家庄）有限公司	一种奥贝胆酸片剂及其制备方法
US10828305B2 (en)	2016-03-01	2020-11-10	Shanghai Pharmaceuticals Holding Co., Ltd.	Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
IL301979B2 (en) *	2017-03-30	2024-05-01	Merck Patent Gmbh	Spray dried solid dispersions comprising (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation
MA49059A (fr)	2017-04-28	2021-03-24	Seagen Inc	Traitement des cancers positifs à her2
TWI780270B (zh) *	2017-11-28	2022-10-11	靜岡縣公立大學法人	固體分散體
WO2019152711A1 (en)	2018-01-31	2019-08-08	Diciphera Pharmaceuticals Llc.	Combination therapy for the treatment of gastrointestinal stromal tumors
WO2019152719A1 (en)	2018-01-31	2019-08-08	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
WO2019193488A1 (en) *	2018-04-06	2019-10-10	Capsugel Belgium Nv	Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CN109942576B (zh) *	2019-03-07	2020-09-11	上海工程技术大学	Irbinitinib及中间体的制备方法
CN111825604A (zh) *	2019-04-16	2020-10-27	宁波药腾医药科技有限公司	一种图卡替尼及其中间产物的合成方法
CA3150433A1 (en)	2019-08-12	2021-02-18	Deciphera Pharmaceuticals, Llc	Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en)	2019-08-12	2021-02-18	Deciphera Pharmaceuticals, Llc	Ripretinib for treating gastrointestinal stromal tumors
CN114615977B (zh) *	2019-09-19	2025-01-14	诺沃挪第克健康护理股份公司	丙酮酸激酶r(pkr)活化组合物
CA3156820A1 (en)	2019-10-21	2021-04-29	Seagen Inc.	Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
WO2021097220A1 (en)	2019-11-15	2021-05-20	Seagen Inc.	Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
FI4084778T3 (fi) *	2019-12-30	2023-12-18	Deciphera Pharmaceuticals Llc	Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
FI4084779T3 (fi)	2019-12-30	2024-12-16	Deciphera Pharmaceuticals Llc	1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
JP2023527794A (ja)	2020-05-29	2023-06-30	シージェンインコーポレイテッド	トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法
CA3189333A1 (en)	2020-07-29	2022-02-03	Seagen Inc.	Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
CN115340541B (zh) *	2022-07-01	2024-01-30	上海艾洋化学科技有限公司	一种妥卡替尼中间体的制备方法
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
CN115650977A (zh) *	2022-10-09	2023-01-31	广东润兴生物科技有限公司	一种妥卡替尼的合成方法
WO2024191826A1 (en)	2023-03-10	2024-09-19	Seagen Inc.	Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors
WO2024206858A1 (en)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
CN118084901A (zh) *	2023-12-15	2024-05-28	江苏希迪制药有限公司	妥卡替尼的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6350786B1 (en)	1998-09-22	2002-02-26	Hoffmann-La Roche Inc.	Stable complexes of poorly soluble compounds in ionic polymers
CA2431319A1 (en) *	2000-12-11	2002-06-20	Hiroto Bando	Pharmaceutical composition having an improved water solubility
WO2002048142A1 (fr) *	2000-12-11	2002-06-20	Takeda Chemical Industries, Ltd.	Compositions medicamenteuses presentant une meilleure absorbabilite
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
CN102432552B (zh)	2003-08-14	2016-01-20	阿雷生物药品公司	作为受体酪氨酸激酶抑制剂的喹唑啉类似物
GB0321648D0 (en)	2003-09-16	2003-10-15	Astrazeneca Ab	Quinazoline derivatives
RU2400227C2 (ru) *	2004-04-08	2010-09-27	Вайет	Состав, содержащий твердую дисперсию базедоксифен ацетата
JP5134548B2 (ja) *	2005-11-15	2013-01-30	アレイバイオファーマ、インコーポレイテッド	過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
US9101617B2 (en) *	2007-04-20	2015-08-11	Daido Chemical Corporation	Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
EP2155166A2 (en) *	2007-05-11	2010-02-24	F. Hoffmann-Roche AG	Pharmaceutical compositions for poorly soluble drugs
US20120052061A1 (en) *	2007-09-24	2012-03-01	Tragara Pharmaceuticals Inc.	Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
CA2723398C (en) *	2008-05-05	2017-07-04	Abbott Gmbh & Co. Kg	Method for evaluating the solubility of a crystalline substance in a polymer
EP2158912A1 (en) *	2008-08-25	2010-03-03	Ratiopharm GmbH	Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2253306A1 (en) *	2009-05-18	2010-11-24	Royal College of Surgeons in Ireland	Orodispersible dosage forms containing solid drug dispersions
DK2765990T3 (da) *	2011-10-14	2017-11-13	Array Biopharma Inc	Faststofdispersion
KR20200003245A (ko)	2011-10-14	2020-01-08	어레이 바이오파마 인크.	선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
TR201808450T4 (tr)	2012-03-23	2018-07-23	Array Biopharma Inc	Beyin kanserinin tedavisinde kullanılmaya yönelik amorf katı dispersiyon.

2012
- 2012-10-12 DK DK12809373.9T patent/DK2765990T3/da active
- 2012-10-12 WO PCT/US2012/060044 patent/WO2013056108A2/en active Application Filing
- 2012-10-12 CN CN201810490376.3A patent/CN108498465B/zh active Active
- 2012-10-12 MY MYPI2014700908A patent/MY169072A/en unknown
- 2012-10-12 ES ES12809373.9T patent/ES2650608T3/es active Active
- 2012-10-12 JP JP2014535944A patent/JP5944514B2/ja active Active
- 2012-10-12 EP EP12809373.9A patent/EP2765990B1/en active Active
- 2012-10-12 RU RU2014119283A patent/RU2648448C2/ru active
- 2012-10-12 US US14/351,840 patent/US9457093B2/en active Active
- 2012-10-12 MX MX2014004551A patent/MX353970B/es active IP Right Grant
- 2012-10-12 PL PL12809373T patent/PL2765990T3/pl unknown
- 2012-10-12 PH PH1/2014/500799A patent/PH12014500799B1/en unknown
- 2012-10-12 BR BR112014009092-0A patent/BR112014009092B1/pt active IP Right Grant
- 2012-10-12 SI SI201231101T patent/SI2765990T1/sl unknown
- 2012-10-12 RS RS20171188A patent/RS56608B1/sr unknown
- 2012-10-12 CA CA3114454A patent/CA3114454C/en active Active
- 2012-10-12 LT LTEP12809373.9T patent/LT2765990T/lt unknown
- 2012-10-12 CA CA2852058A patent/CA2852058C/en active Active
- 2012-10-12 AU AU2012322039A patent/AU2012322039C1/en active Active
- 2012-10-12 ME MEP-2017-256A patent/ME02913B/me unknown
- 2012-10-12 BR BR122020010643-3A patent/BR122020010643B1/pt active IP Right Grant
- 2012-10-12 HU HUE12809373A patent/HUE035247T2/hu unknown
- 2012-10-12 CN CN201280061909.7A patent/CN103998023B/zh active Active
- 2012-10-12 CN CN202210434174.3A patent/CN114886853A/zh active Pending
- 2012-10-12 KR KR1020147012944A patent/KR102000312B1/ko active Active
- 2012-10-12 PT PT128093739T patent/PT2765990T/pt unknown
- 2012-10-12 SG SG11201401459YA patent/SG11201401459YA/en unknown
- 2012-10-12 SM SM20170499T patent/SMT201700499T1/it unknown
- 2012-10-15 TW TW101137971A patent/TWI594769B/zh active
- 2012-10-15 TW TW106116008A patent/TWI722189B/zh active
- 2012-10-15 TW TW109141025A patent/TWI788733B/zh active
2014
- 2014-04-11 CL CL2014000930A patent/CL2014000930A1/es unknown
- 2014-04-13 IL IL232103A patent/IL232103B/en active IP Right Grant
- 2014-05-14 CO CO14103943A patent/CO6960547A2/es unknown
- 2014-05-14 CR CR20140228A patent/CR20140228A/es unknown
2015
- 2015-11-13 JP JP2015223018A patent/JP2016027062A/ja active Pending
2016
- 2016-09-05 ZA ZA2016/06123A patent/ZA201606123B/en unknown
- 2016-09-23 US US15/275,163 patent/US20170136022A1/en not_active Abandoned
2017
- 2017-07-31 AU AU2017210499A patent/AU2017210499C1/en active Active
- 2017-10-17 HR HRP20171578TT patent/HRP20171578T1/hr unknown
- 2017-10-30 CY CY20171101121T patent/CY1119837T1/el unknown
2019
- 2019-01-15 AU AU2019200243A patent/AU2019200243C1/en active Active
- 2019-03-14 US US16/353,951 patent/US20190275043A1/en not_active Abandoned
2020
- 2020-12-23 US US17/133,094 patent/US20210220361A1/en not_active Abandoned
2021
- 2021-07-09 NO NO2021029C patent/NO2021029I1/no unknown
2022
- 2022-08-25 US US17/895,951 patent/US20230097309A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR122020010643B1 (pt)	2022-05-17
TW201330876A (zh)	2013-08-01
CA3114454A1 (en)	2013-04-18
BR112014009092A2 (pt)	2017-04-18
CN108498465B (zh)	2022-05-17
CN103998023B (zh)	2018-06-15
TW202131902A (zh)	2021-09-01
JP2014528484A (ja)	2014-10-27
AU2017210499B2 (en)	2019-01-24
CN108498465A (zh)	2018-09-07
PH12014500799B1 (en)	2019-04-26
ME02913B (me)	2018-04-20
HUE035247T2 (hu)	2018-05-02
CY1119837T1 (el)	2018-06-27
CA3114454C (en)	2022-11-29
PH12014500799A1 (en)	2014-05-12
EP2765990A2 (en)	2014-08-20
SMT201700499T1 (it)	2017-11-15
RU2014119283A (ru)	2015-11-20
KR102000312B1 (ko)	2019-07-15
HRP20171578T1 (hr)	2017-12-01
TW201728323A (zh)	2017-08-16
CR20140228A (es)	2014-08-21
IL232103A0 (en)	2014-05-28
AU2012322039B2 (en)	2017-08-17
AU2017210499C1 (en)	2021-04-29
CN103998023A (zh)	2014-08-20
CL2014000930A1 (es)	2014-07-18
MX353970B (es)	2018-02-07
US20170136022A1 (en)	2017-05-18
US20190275043A1 (en)	2019-09-12
ZA201606123B (en)	2021-05-26
TWI788733B (zh)	2023-01-01
US20230097309A1 (en)	2023-03-30
CA2852058C (en)	2021-06-01
TWI722189B (zh)	2021-03-21
ES2650608T3 (es)	2018-01-19
SI2765990T1 (sl)	2017-11-30
PL2765990T3 (pl)	2018-01-31
NZ624942A (en)	2016-06-24
EP2765990B1 (en)	2017-09-06
AU2012322039C1 (en)	2021-04-29
SG11201401459YA (en)	2014-07-30
WO2013056108A3 (en)	2013-06-27
AU2019200243C1 (en)	2021-04-29
US20210220361A1 (en)	2021-07-22
TWI594769B (zh)	2017-08-11
MX2014004551A (es)	2015-02-12
CA2852058A1 (en)	2013-04-18
BR112014009092B1 (pt)	2022-01-18
RS56608B1 (sr)	2018-02-28
AU2012322039A1 (en)	2014-06-05
IL232103B (en)	2018-11-29
CO6960547A2 (es)	2014-05-30
JP2016027062A (ja)	2016-02-18
MY169072A (en)	2019-02-12
LT2765990T (lt)	2018-01-25
US20140296267A1 (en)	2014-10-02
KR20140075798A (ko)	2014-06-19
WO2013056108A2 (en)	2013-04-18
JP5944514B2 (ja)	2016-07-05
NO2021029I1 (no)	2021-07-09
AU2019200243B2 (en)	2020-06-11
PT2765990T (pt)	2017-11-14
AU2017210499A1 (en)	2017-08-17
AU2019200243A1 (en)	2019-01-31
US9457093B2 (en)	2016-10-04
CN114886853A (zh)	2022-08-12
RU2648448C2 (ru)	2018-03-26

Publication	Publication Date	Title
NO2021029I1 (no)	2021-07-09	tukatinib
EP2695849A4 (en)	2015-07-01	MICRO PUMP
HUE037048T2 (hu)	2018-08-28	Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
DK3467500T3 (da)	2021-08-16	Cobinder-understøttede assayfremgangsmåder
BR112014002399A2 (pt)	2017-02-21	conjunto
IL231351A0 (en)	2014-04-30	Amino-substituted imidazopyridazines
HK1249026A1 (zh)	2018-10-26	艾杜糖-2-硫酸酯酶的純化
AR092198A1 (es)	2015-04-08	Derivados de pirazolopirimidinas
BR112014003878A2 (pt)	2017-03-21	síntese de r-bifenilalaninol
IT1404805B1 (it)	2013-11-29	Disperdenti
PT2736340T (pt)	2018-03-22	Biocontrolo de nemátodos
EP2768739A4 (en)	2015-10-21	EYEWASH FLUID CONTAINER
EP2738076A4 (en)	2015-04-08	SUSPENSION DEVICE
DE112012002915A5 (de)	2014-03-27	Ausrückeinrichtung
EP2691361A4 (en)	2014-09-17	SYNTHESIS OF DIAZIDEN
EP2858975A4 (en)	2015-12-09	FBXO3 INHIBITORS
EP2714694A4 (en)	2014-11-05	BAKTERIOCHLORIMIDE
ES1080381Y (es)	2013-08-26	Fachada de medios
EP2842958A4 (en)	2015-09-02	NAPHTHOBISTHIADIAZOLDERIVAT
EP2738025A4 (en)	2015-08-05	SUSPENSION DEVICE
BR112014013814A2 (pt)	2017-06-13	decantador
EP2804607A4 (en)	2015-08-12	SYNTHESIS OF RALTEGRAVIR
FR2955136B1 (fr)	2012-01-20	Arret de vantail
FR2997080B1 (fr)	2015-11-27	Inhibiteurs de neprilysine
NO20111461A1 (no)	2013-03-04	Gradrennelist